Astria Therapeutics to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema

Reuters

Oct 31, 2025

Astria <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema

Astria Therapeutics Inc. announced that it will present final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart in individuals with hereditary angioedema $(HAE)$ at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting. The meeting is scheduled to take place from November 6-10, 2025, in Orlando, Florida. The results will be presented by Dr. Aleena Banerji of Harvard Medical School on November 8, 2025, during a poster session in the West Exhibit Hall. The data to be presented will provide additional information from the clinical trial evaluating navenibart for HAE.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251031805612) on October 31, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579693684"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579693684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579693684?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579693684","market":"us","top_or_hot":-1,"title":"Astria Therapeutics to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ATXS\">Astria Therapeutics Inc</a>. announced that it will present final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart in individuals with hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting. The meeting is scheduled to take place from November 6-10, 2025, in Orlando, Florida. The results will be presented by Dr. Aleena Banerji of Harvard Medical School on November 8, 2025, during a poster session in the West Exhibit Hall. The data to be presented will provide additional information from the clinical trial evaluating navenibart for HAE.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251031805612) on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astria Therapeutics to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstria Therapeutics to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-31 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ATXS\">Astria Therapeutics Inc</a>. announced that it will present final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart in individuals with hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting. The meeting is scheduled to take place from November 6-10, 2025, in Orlando, Florida. The results will be presented by Dr. Aleena Banerji of Harvard Medical School on November 8, 2025, during a poster session in the West Exhibit Hall. The data to be presented will provide additional information from the clinical trial evaluating navenibart for HAE.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251031805612) on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL7PKPwF:1","article_id":"2579693684","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579693684","pubTimestamp":1761912036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Astria Therapeutics Inc. announced that it will present final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart in individuals with hereditary angioedema  at the upcoming American College of Allergy, Asthma, and Immunology  Annual Scientific Meeting. The meeting is scheduled to take place from November 6-10, 2025, in Orlando, Florida. The results will be presented by Dr. Aleena Banerji of Harvard Medical School on November 8, 2025, during a poster session in the West Exhibit Hall. The data to be presented will provide additional information from the clinical trial evaluating navenibart for HAE.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATXS":"Astria Therapeutics Inc"},"translate_title":"Astria Therapeutics将公布Navenibart治疗遗传性血管性水肿的最终ALPHA-STAR试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATXS":0.9},"content_text":"Astria Therapeutics to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema\n    \n\nAstria Therapeutics Inc. announced that it will present final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart in individuals with hereditary angioedema $(HAE)$ at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting. The meeting is scheduled to take place from November 6-10, 2025, in Orlando, Florida. The results will be presented by Dr. Aleena Banerji of Harvard Medical School on November 8, 2025, during a poster session in the West Exhibit Hall. The data to be presented will provide additional information from the clinical trial evaluating navenibart for HAE.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251031805612) on October 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}